Pfizer Inc. logo
Pfizer Inc. (PFE)
Compare

Pfizer Inc. (PFE) EV/Assets Ratio: 1.03x

popular:market cap|pe ratio|revenue|price history|total return

Is Pfizer Inc.’s EV/Assets ratio high or low?

Pfizer Inc.'s EV/Assets ratio of 1.03x is 20% below its 5-year average of 1.28x, near the low end of its 5-year range (0.88x–2.16x).

As of Thursday, June 11, 2026. 2.99% above its 12-month average of 1.00x.

Enterprise Value|EV/Sales|Total Assets|All Metrics

PFE EV/Assets Ratio Chart

PFE EV/Assets Ratio
1.03x+7.29% 1Y
Zoom

PFE Average EV/Assets Ratio Chart

PFE Current vs Average EV/Assets Ratio Chart

PFE EV/Assets Ratio Metrics

EV/ASSETS RATIO

1.03x

EV/ASSETS RATIO AVG TTM

1.00x

EV/ASSETS RATIO AVG 3Y

1.03x

EV/ASSETS RATIO AVG 5Y

1.28x

EV/ASSETS RATIO AVG 10Y

1.39x

EV/ASSETS RATIO AVG 15Y

1.34x

EV/ASSETS RATIO AVG 20Y

1.31x

CURRENT VS TTM AVG

+2.99%

CURRENT VS 3Y AVG

+0.01%

CURRENT VS 5Y AVG

-19.63%

CURRENT VS 10Y AVG

-26.06%

CURRENT VS 15Y AVG

-23.12%

CURRENT VS 20Y AVG

-21.32%

PFE Competitors' EV/Assets Ratio

NAMEMARKET CAPEV/ASSETS RATIOTTM3Y5Y
Pfizer Inc. (PFE)$149.61B1.03x1.00x1.03x1.28x
Intuitive Surgical, Inc. (ISRG)$144.79B7.27x8.88x9.09x8.50x
Abbott Laboratories (ABT)$155.75B1.66x2.50x2.67x2.75x
Gilead Sciences, Inc. (GILD)$156.35B2.97x3.05x2.44x2.15x
CVS Health Corporation (CVS)$126.70B0.77x0.67x0.63x0.70x
Danaher Corporation (DHR)$126.39B1.72x1.98x2.16x2.26x
Thermo Fisher Scientific Inc. (TMO)$176.21B1.92x2.16x2.33x2.57x
Bristol-Myers Squibb Company (BMY)$116.13B1.75x1.55x1.56x1.64x
Amgen Inc. (AMGN)$188.37B2.48x2.46x2.27x2.38x
Vertex Pharmaceuticals Incorporated (VRTX)$110.59B4.12x4.45x4.69x4.46x

Pfizer Inc. EV/Assets Ratio Formula & Definition

EV/Assets compares enterprise value to total assets. It is useful for asset-heavy businesses and for comparing how much the market pays for each dollar of assets.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Pfizer Inc. EV/Assets Ratio FAQ

What is the EV/Assets ratio for Pfizer Inc. (PFE)?
The EV/Assets ratio for PFE stock is 1.03x.
Is Pfizer Inc.'s EV/Assets ratio high or low?
Pfizer Inc.'s EV/Assets ratio of 1.03x is 20% below its 5-year average of 1.28x, near the low end of its 5-year range (0.88x–2.16x).
What is the TTM average EV/Assets ratio for Pfizer Inc. (PFE)?
The TTM average EV/Assets ratio for PFE stock is 1.00x.
What is the 3Y average EV/Assets ratio for Pfizer Inc. (PFE)?
The 3Y average EV/Assets ratio for PFE stock is 1.03x.
What is the 5Y average EV/Assets ratio for Pfizer Inc. (PFE)?
The 5Y average EV/Assets ratio for PFE stock is 1.28x.
What is the 10Y average EV/Assets ratio for Pfizer Inc. (PFE)?
The 10Y average EV/Assets ratio for PFE stock is 1.39x.
What is the 15Y average EV/Assets ratio for Pfizer Inc. (PFE)?
The 15Y average EV/Assets ratio for PFE stock is 1.34x.
What is the 20Y average EV/Assets ratio for Pfizer Inc. (PFE)?
The 20Y average EV/Assets ratio for PFE stock is 1.31x.

Pfizer Inc. EV/Assets Ratio History

DATEEV/ASSETS RATIO
2026-06-111.03x
2026-06-101.01x
2026-06-091.01x
2026-06-081.01x
2026-06-051.02x
2026-06-041.01x
2026-06-031.00x
2026-06-021.01x
2026-06-011.01x
2026-05-291.02x
2026-05-281.02x
2026-05-271.03x
2026-05-261.02x
2026-05-221.02x
2026-05-211.02x
2026-05-201.01x
2026-05-191.01x
2026-05-181.00x
2026-05-151.00x
2026-05-141.01x
2026-05-131.02x
2026-05-121.02x
2026-05-111.01x
2026-05-081.01x
2026-05-071.03x
2026-05-061.03x
2026-05-051.03x
2026-05-041.04x
2026-05-011.04x
2026-04-301.05x
2026-04-291.04x
2026-04-281.04x
2026-04-271.05x
2026-04-241.06x
2026-04-231.05x
2026-04-221.05x
2026-04-211.06x
2026-04-201.07x
2026-04-171.07x
2026-04-161.06x
2026-04-151.06x
2026-04-141.06x
2026-04-131.07x
2026-04-101.05x
2026-04-091.06x
2026-04-081.07x
2026-04-071.06x
2026-04-061.08x
2026-04-021.09x
2026-04-011.10x
2026-03-311.09x
2026-03-301.08x
2026-03-271.06x
2026-03-261.07x
2026-03-251.06x
2026-03-241.05x
2026-03-231.05x
2026-03-201.06x
2026-03-191.07x
2026-03-181.06x
2026-03-171.07x
2026-03-161.05x
2026-03-131.04x
2026-03-121.05x
2026-03-111.06x
2026-03-101.06x
2026-03-091.05x
2026-03-061.06x
2026-03-051.05x
2026-03-041.05x
2026-03-031.04x
2026-03-021.06x
2026-02-271.07x
2026-02-261.06x
2026-02-251.03x
2026-02-241.03x
2026-02-231.03x
2026-02-201.02x
2026-02-191.02x
2026-02-181.04x
2026-02-171.04x
2026-02-131.04x
2026-02-121.04x
2026-02-111.05x
2026-02-101.05x
2026-02-091.03x
2026-02-061.03x
2026-02-051.01x
2026-02-041.02x
2026-02-030.99x
2026-02-021.02x
2026-01-301.01x
2026-01-291.00x
2026-01-281.00x
2026-01-271.01x
2026-01-261.00x
2026-01-230.99x
2026-01-221.00x
2026-01-211.00x
2026-01-200.99x
2026-01-160.99x
2026-01-151.00x
2026-01-140.99x
2026-01-130.98x
2026-01-120.98x
2026-01-090.99x
2026-01-080.98x
2026-01-070.98x
2026-01-060.99x
2026-01-050.98x
2026-01-020.98x
2025-12-310.97x
2025-12-300.97x
2025-12-290.97x
2025-12-260.98x
2025-12-240.97x
2025-12-230.97x
2025-12-220.98x
2025-12-190.98x
2025-12-180.97x
2025-12-170.97x
2025-12-160.99x
2025-12-151.01x
2025-12-121.00x
2025-12-111.00x
2025-12-100.99x
2025-12-090.98x
2025-12-080.99x
2025-12-051.00x
2025-12-040.99x
2025-12-030.99x
2025-12-020.98x
2025-12-010.98x
2025-11-280.99x
2025-11-260.99x
2025-11-250.99x
2025-11-240.98x
2025-11-210.97x
2025-11-200.96x
2025-11-190.97x
2025-11-180.99x
2025-11-170.98x
2025-11-140.98x
2025-11-131.00x
2025-11-121.00x
2025-11-110.99x
2025-11-100.96x
2025-11-070.96x
2025-11-060.97x
2025-11-050.96x
2025-11-040.95x
2025-11-030.97x
2025-10-310.97x
2025-10-300.96x
2025-10-290.96x
2025-10-280.97x
2025-10-270.98x
2025-10-240.98x
2025-10-230.97x
2025-10-220.98x
2025-10-210.98x
2025-10-200.98x
2025-10-170.97x
2025-10-160.96x
2025-10-150.97x
2025-10-140.97x
2025-10-130.98x
2025-10-100.98x
2025-10-090.99x
2025-10-081.00x
2025-10-071.02x
2025-10-061.02x
2025-10-031.05x
2025-10-021.04x
2025-10-011.05x
2025-09-301.00x
2025-09-290.95x
2025-09-260.95x
2025-09-250.95x
2025-09-240.96x
2025-09-230.96x
2025-09-220.96x
2025-09-190.96x
2025-09-180.96x
2025-09-170.96x
2025-09-160.95x
2025-09-150.96x
2025-09-120.95x
2025-09-110.98x
2025-09-100.97x
2025-09-090.98x
2025-09-080.97x
2025-09-050.98x
2025-09-040.97x
2025-09-030.98x
2025-09-020.98x
2025-08-290.98x
2025-08-280.97x
2025-08-270.99x
2025-08-260.98x
2025-08-250.99x
2025-08-221.01x
2025-08-211.00x
2025-08-200.99x
2025-08-190.99x
2025-08-180.99x
2025-08-150.99x
2025-08-140.99x
2025-08-130.99x
2025-08-120.97x
2025-08-110.97x
2025-08-080.97x
2025-08-070.96x
2025-08-060.95x
2025-08-050.98x
2025-08-040.93x
2025-08-010.93x
2025-07-310.93x
2025-07-300.94x
2025-07-290.95x
2025-07-280.96x
2025-07-250.97x
2025-07-240.98x
2025-07-230.98x
2025-07-220.98x
2025-07-210.95x
2025-07-180.96x
2025-07-170.96x
2025-07-160.96x
2025-07-150.96x
2025-07-140.98x
2025-07-110.99x
2025-07-101.00x
2025-07-090.99x
2025-07-080.99x
2025-07-070.98x
2025-07-030.98x
2025-07-020.98x
2025-07-010.98x
2025-06-300.95x
2025-06-270.95x
2025-06-260.95x
2025-06-250.95x
2025-06-240.96x
2025-06-230.95x
2025-06-200.95x
2025-06-180.94x
2025-06-170.95x
2025-06-160.96x
2025-06-130.96x
2025-06-120.97x
2025-06-110.96x
2025-06-100.95x
2025-06-090.95x
2025-06-060.93x
2025-06-050.92x
2025-06-040.93x
2025-06-030.93x
2025-06-020.93x
2025-05-300.93x

Showing the most recent 260 of 5,032 data points. The chart above shows the full history.

Related Metrics

Enterprise ValueEV/SalesTotal AssetsAll Metrics

About Pfizer Inc.

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

New York City, NY
81,000 employees
www.pfizer.com
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Albert Bourla
View full financials